Stock XLO XILIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Delayed Nasdaq
Other stock markets
 01:15:30 03/05/2024 am IST 		5-day change 1st Jan Change
1.05 USD -2.78% Intraday chart for Xilio Therapeutics, Inc. +4.95% +92.73%
19/04 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
01/04 Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Xilio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sector Update: Health Care Stocks Slide Late Afternoon
Top Midday Gainers
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures
Top Premarket Gainers
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12
Xilio Therapeutics, Inc. Enters Exclusive License Agreement with Gilead Sciences, Inc
Xilio Therapeutics, Inc. Plans Workforce Reduction
Xilio Therapeutics, Inc. Reports Additional Data from Its Phase 2 Clinical Trial Evaluating XTX202
Xilio Therapeutics, Inc. Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101
Xilio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Xilio Therapeutics Shares Rise Following Initial Phase 1/2 Data on XTX202
Xilio Therapeutics, Inc. Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202
Xilio Therapeutics Announces Board Changes
Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Xilio Therapeutics Names New Chief Operating Officer
Xilio Therapeutics, Inc. Announces Promotion of Chris Frankenfield to Chief Operating Officer
Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XLO Stock
  4. News Xilio Therapeutics, Inc.
  5. Other languages